Subgroup analysis of confirmed ORR by PD-L1 TC and IC expression for (A) durvalumab plus tremelimumab plus EP versus EP and (B) durvalumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of responses. Groups are not plotted when there are ≤5 responses across both arms.

Durvalumab

Tremelimumab

10.1158/1078-0432.27095569.v1

Cite

Citations (0)

Supplementary Table S3 from Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

Luís Paz-Ares Marina Chiara Garassino Yuanbin Chen Niels Reinmuth Katsuyuki Hotta

Summary of adverse events of any cause in the PD-L1, tTMB, and overall safety populations.

Durvalumab

Tremelimumab

10.1158/1078-0432.27095542

Cite

Citations (0)

Supplementary Figure S9 from Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

Luís Paz-Ares Marina Chiara Garassino Yuanbin Chen Niels Reinmuth Katsuyuki Hotta

Distribution of tTMB scores by treatment arm in the tTMB BEP.

Durvalumab

Tremelimumab

10.1158/1078-0432.27095554

Cite

Citations (0)

P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN

Journal of Thoracic Oncology (2021)

Niels Reinmuth Marina Chiara Garassino Dmytro Trukhin Maximilian J. Hochmair Mustafa Özgüroğlu

Durvalumab

Carboplatin

Interim analysis

Interim

10.1016/j.jtho.2021.01.873

Cite

Citations (7)

Supplementary Figure S10 from Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

Luís Paz-Ares Marina Chiara Garassino Yuanbin Chen Niels Reinmuth Katsuyuki Hotta

Kaplan-Meier analysis of OS for (A) the tTMB <10 mut/Mb subgroup and (B) the tTMB ≥10 mut/Mb subgroup.

Durvalumab

Tremelimumab

10.1158/1078-0432.25232330

Cite

Citations (0)

Supplementary Figure S7 from Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

Luís Paz-Ares Marina Chiara Garassino Yuanbin Chen Niels Reinmuth Katsuyuki Hotta

Subgroup analysis of confirmed ORR by tTMB for (A) durvalumab plus tremelimumab plus EP versus EP and (B) durvalumab plus EP versus EP. In each panel, the shaded band shows the confidence interval for the ITT population; circle sizes are proportional to the number of responses.

Durvalumab

Tremelimumab

10.1158/1078-0432.25232309

Cite

Citations (0)

Supplementary Figure S11 from Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

Luís Paz-Ares Marina Chiara Garassino Yuanbin Chen Niels Reinmuth Katsuyuki Hotta

Relationship between PD-L1 expression and tTMB score. (A) Box plots showing the distribution of tTMB score in patients by PD-L1 subgroup; (B) Venn diagram showing overlap between the tTMB ≥10 mut/Mb and PD-L1 TC or IC ≥1% subgroups. Percentages are calculated from the PD-L1 and tTMB BEP, i.e., patients who had both a PD-L1 and a tTMB result (n=275); samples from 171 patients had tTMB ≥10 mut/Mb and/or PD-L1 TC or IC ≥1%, while samples from 104 patients (37.8%) had both tTMB <10 mut/Mb and PD-L1 TC and IC <1%.

Durvalumab

Tremelimumab

10.1158/1078-0432.25232327.v1

Cite

Citations (0)